Literature DB >> 7810698

Proteinuria and impaired glomerular permselectivity in uninephrectomized fawn-hooded rats.

J D Oliver1, J L Simons, J L Troy, A P Provoost, B M Brenner, W M Deen.   

Abstract

Previous studies of glomerular permselectivity have indicated that both size selectivity and charge selectivity changes play a role in the pathogenesis of proteinuria. In this study, we measured Ficoll sieving coefficients, hemodynamic parameters, and urinary protein excretion rates in the FHH strain of fawn-hooded rats. These animals spontaneously develop systemic and glomerular hypertension, proteinuria, and focal and segmental glomerulosclerosis at a relatively young age. Three groups of FHH rats were studied: two-kidney controls (2K), untreated uninephrectomized rats (CON-NX), and uninephrectomized rats treated with the angiotensin I converting enzyme inhibitor enalapril (ENA-NX). CON-NX rats had higher glomerular transcapillary pressures (delta P) and higher urinary excretion rates of both total protein (UpV) and albumin (UaV) than did 2K rats, whereas treatment with enalapril prevented both glomerular hypertension and the increased proteinuria. Ficoll sieving coefficients were significantly higher in both groups of NX rats compared with 2K rats only for Stokes-Einstein radii (rs) > or = 46 A. Fits of sieving data to pore models showed a small increase in the number of large, nonselective pores in NX, which was not prevented by enalapril treatment. Total clearances of Ficoll with rs = 36 A (the size of albumin) in CON-NX and ENA-NX groups were unchanged compared with 2K animals. In contrast, UaV in CON-NX rats was more than six times that of 2K and ENA-NX rats. Across groups, UpV, UaV, and the ratio (UaV)/(UpV) all correlated strongly with delta P.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7810698     DOI: 10.1152/ajprenal.1994.267.6.F917

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  Hyperfiltration nephropathy as a cause of late graft loss in renal transplantation.

Authors:  C Modlin; D Goldfarb; A C Novick
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

2.  C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria.

Authors:  Gopala K Rangan
Journal:  World J Nephrol       Date:  2016-05-06

3.  Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats.

Authors:  Ludmilla Le Berre; Yann Godfrin; Eberhard Günther; Françoise Buzelin; Sabine Perretto; Helga Smit; Dontscho Kerjaschki; Claire Usal; Cristina Cuturi; Jean-Paul Soulillou; Jacques Dantal
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 4.  Renal albumin filtration: alternative models to the standard physical barriers.

Authors:  Marcus J Moeller; Verena Tenten
Journal:  Nat Rev Nephrol       Date:  2013-03-26       Impact factor: 28.314

5.  Mechanisms of impaired nephrogenesis with fetal growth restriction: altered renal transcription and growth factor expression.

Authors:  Ahmed K Abdel-Hakeem; Tasmia Q Henry; Thomas R Magee; Mina Desai; Michael G Ross; Roy Z Mansano; John S Torday; Cynthia C Nast
Journal:  Am J Obstet Gynecol       Date:  2008-07-17       Impact factor: 8.661

6.  Induction of T regulatory cells attenuates idiopathic nephrotic syndrome.

Authors:  Ludmilla Le Berre; Sarah Bruneau; Jeanne Naulet; Karine Renaudin; Françoise Buzelin; Claire Usal; Helga Smit; Thomas Condamine; Jean-Paul Soulillou; Jacques Dantal
Journal:  J Am Soc Nephrol       Date:  2008-11-19       Impact factor: 10.121

7.  Lack of renoprotective effect of chronic intravenous angiotensin-(1-7) or angiotensin-(2-10) in a rat model of focal segmental glomerulosclerosis.

Authors:  Juan Carlos Q Velez; Michael G Janech; Megan P Hicks; Thomas A Morinelli; Jessalyn Rodgers; Sally E Self; John M Arthur; Wayne R Fitzgibbon
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.